We have developed a micro-injection technique to deliver recombinant adenovirus and AAV to mouse fetuses at day 15 after conception. Several routes of delivery, including injections to the amniotic fluid, the front limb, the placenta, the liver, and the retro-orbital venus plexus, were tested using an E1-deleted recombinant adenovirus (Ad.CBlacZ) or a recombinant adeno-associated virus (AAV.CMVlacZ) carrying a ␤-galactosidase (lacZ) gene. Injection of Ad.CBlacZ into the amniotic cavity led to transgene expression in the skin and in the digestive tract of the fetuses. Injection of Ad.CBlacZ in the front limb resulted in LacZ expression in all major muscle groups around the injection site and at low levels in the liver. The other three routes of delivery, ie intraplacental, intra-hepatic and retro-orbital injections of Ad.CBlacZ, all led to lacZ expression predominantly in the liver. Further studies revealed a maximal tolerant dose
Introduction
In utero gene transfer offers an alternative approach for the treatment of genetic diseases, especially those diseases with devastating consequences before post-natal life when conventional treatment can be initiated. The early intervention might also allow targeting of the still expanding stem cell populations of organ or cell systems that are no longer accessible in later life. Moreover, it might help avoid immune sensitization against the vector system or transgene product, thus allowing its persistent expression. Earlier animal studies demonstrated the feasibility of introducing a new gene into the developing fetus, although the optimal timing and best mode of delivery have yet to be defined.
The most commonly used vectors for in utero gene transfer are retroviruses and adenoviruses. Retroviral vectors have the advantage of being able to incorporate into the host cell genome and therefore have the potential to achieve life-long correction of the defective gene. Retrovirus-mediated gene transfer in lungs of living fetal (defined as the highest viral dose with р20% mortality in the injected fetuses) of 1 × 10 9 particles per fetus for intrahepatic injections, 3 × 10 9 particles per fetus for intra-placental injection, 1 × 10 10 particles per fetus for retro-orbital and intra-amniotic injections, and 2 × 10 10 particle per fetus for intra-muscular injection. The adenovirus-mediated lacZ expression in liver and muscle persisted for at least 6 weeks. Intra-muscular injection of AAV.CMVlacZ also resulted in lacZ expression in the muscle up to 3 months after birth with no indication of cellular immune response at the injection site. Taken together, our results demonstrated that prolonged transgene expression can be achieved by in utero gene transfer using either adenoviral or AAV vectors. The distribution of virus-mediated gene transfer appeared to determined mostly by the route of viral administration. Gene Therapy (2000) 7, 1986-1992. sheep and livers of fetal mice have been achieved. 1, 2 Long-term retrovirus-mediated gene expression up to 5 years after injection in fetal sheep has also been reported. 3 The major disadvantage of using a retroviral vector is the low efficiency of transduction since the vectors require dividing cells for infection, and are unstable in vivo in the presence of some body fluids. 4 Adenoviral vectors, on the other hand, can effectively infect both dividing and nondividing cells and achieve high levels of transgene expression. A number of studies have demonstrated successful in utero adenovirusmediated gene transfer to fetal sheep, rabbits and mice using a variety of routes of delivery. 2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Virus-mediated lacZ expression in mice up to 2 months after viral administration has been reported. 2 It was shown that a single in utero dose of a recombinant adenovirus containing the human CFTR gene successfully reversed the lethal phenotype in a CFTR knockout mouse model. 9, 11 Shortterm correction of factor VIII deficiency in a murine model of hemophilia A by adenovirus-mediated in utero gene transfer of factor VIII was also reported.
14 Although cellular and humoral immune responses to viral gene products have been observed in sheep and rabbit models, which limited the duration of transgene expression and prevented the readministration of the same vectors, 5, 6, 12, 17 little immune response has been observed in fetal mice.
However, the level and distribution of transgene expression varied significantly depending on the route of viral administration.
A new candidate for in utero gene transfer is adenoassociated virus (AAV). Similar to adenovirus, AAV can infect both dividing and nondividing cells but has reduced immunogenicity compared with adenovirus. AAV is capable of integrating into the host genome and therefore has the potential of achieving long-term transgene expression in the target tissues. 18 The vector has been widely used for gene transfer in adult and newborn animal models. However, successful in utero gene transfer using AAV vectors has not yet been reported.
In this study, we systematically evaluated the efficacy, distribution and duration of virus-mediated transgene expression in mouse fetuses with regard to the route of delivery, using both adenoviral and AAV vectors.
Results
Adenovirus-mediated gene transfer Mouse fetuses at day 15 post-conception (p.c.) were injected with freshly prepared Ad.CBlacZ. The fetuses were harvested 3 days after the injection and analyzed for lacZ expression by X-gal staining. Liver tissue from representative dams was also harvested and analyzed for lacZ expression in order to determine any possible transplacental infection. A viral dose of 3 × 10 8 particles per fetus was initially used for each route. The doses were gradually increased in half-log intervals until significant mortality in the injected fetuses (Ͼ50%) was observed. Control fetuses were injected with PBS. Although all control fetuses were born alive and showed normal development, fetuses receiving high doses of adenovirus showed significantly increased mortality. The impact of escalating viral doses on the mortality of the injected fetuses for each of the five routes of delivery is summarized in Figure 1 . The mortality rate was clearly dose-and routedependent. The maximum tolerated dose (MTD), arbitrarily defined as the highest viral dose with a mortality rate р20%, was 2 × 10 10 particles per fetus for the intramuscular route, 1 × 10 10 particles per fetus for the retroorbital and intra-amniotic routes, 3 × 10 9 particles per fetus for the intra-placental route, and 1 × 10 9 particles per fetus for the intra-hepatic route.
As shown in Figures 2 and 3 , the distribution of lacZ staining varied significantly among the different routes. The intra-amniotic injection resulted in lacZ expression only in the skin and the inner lumen of the digestive tract of the fetus (Figure 2a and b) . The intra-placental injection led to liver-specific lacZ expression in the fetuses (Figure 2c ). However, expression in the fetal liver was observed only at doses higher than MTD. Moreover, significant lacZ expression was also detected in the dam's liver ( Figure 2d ). The intra-hepatic injection was highly liver-specific (Figure 3a) , although it sometimes resulted in lacZ staining of the abdominal muscle (data not shown). The retro-orbital injection led to lacZ expression predominantly in the liver, facial muscle, and at low levels in the lung, heart and kidney ( One of the major concerns of in utero injection was injection-related damage to the fetuses. To address the injection-related injuries, fetuses receiving in utero injection of Ad.CBlacZ were harvested and evaluated 3 days after the injection. Gross examination of the whole fetuses and microscopic examination of H&E sections did not reveal any pathological changes or organ deformation (data not shown). Long-term evaluation of mice born from the injected fetuses showed normal development and reproduction. It thus appeared that the injection procedure itself did not result in any permanent damage to the fetuses. The eyesight of mice born from retro-orbitally injected fetuses, however, was not tested.
To determine the duration of adenovirus-mediated transgene expression in the injected fetuses, animals born after in utero injection were killed at various ages and were analyzed for lacZ expression in the targeted tissues. LacZ expression was clearly detectable at days 1, 14 and 42 after birth in the liver of animals receiving intrahepatic injections (Figure 5a , b and c) with a decreasing number of lacZ-positive cells over time. In contrast, animals receiving intra-muscular injections showed significant muscle lacZ staining even at day 42 after birth ( Figure 5d ). No lymphocyte infiltration was found in the liver or muscle at any time-point in the examined sections. 
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(a and b) Skin and intestine of a fetus receiving an intra-aminotic injection. Insert in panel b: intestine of a PBS injected fetus. (c) Liver of a fetus receiving intra-placental injection. (d) Dam
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10 genome copies of AAV.CMVlacZ in the front limb or into the liver. The total survival rate was 95% (20 of 21 injected fetuses) for the intra-muscular injection, and 85% (11 of 13 injected fetuses) for the intra-hepatic injection. Animals born after in utero injection were killed at various ages. The targeted tissues (front limb muscle or liver, respectively) were harvested, sectioned and stained for lacZ expression. As shown in Figure 6 , lacZpositive cells were found in the muscle of intra-muscularly injected animals starting at 14 days of age (Figure 6a ). The expression remained at similar or even higher levels after 3 months (Figure 6b ). In contrast, only a few lacZ-positive cells were found in the liver of animals receiving in utero intra-hepatic injection at days 21 or 70 after birth (Figure 6c, d) . No lymphocyte infiltration was found in any of the examined sections. Since the injection volume was limited at 5 l and the AAV stock used in our injection had a concentration of 5 × 10 12 genome copies/ml, 2.5 × 10 10 genome copies per fetus was the highest possible dose that could be tested in our experiments. The maximum tolerated dose was not yet defined for AAV vectors. 
Discussion
In utero gene delivery in mice was technically difficult due to the small size of mouse fetuses. Several routes of delivery, including intra-amniotic, [8] [9] [10] intra-hepatic, 15, 16 intra-peritoneal, 14 ,15 intra-placental, 2 and into yolk sac Gene Therapy vessels 13 have been attempted using adenoviral vectors in mouse fetuses ranging from days 9.5 to 18 p.c. While transgene expression in the gastrointestinal and respiratory tracts was observed with the intra-amniotic route, a b c d
Figure 6 LacZ expression in mice receiving in utero injection of AAV.CMVlacZ. B6/129 F1 fetuses at day 15 p.c. were injected in the liver (intrahepatic) or in the muscle of the front limb (intra-muscular) with 2.5 × 10 10 genome copies of AAV.CMVlacZ. Animals born after in utero injection were killed at the indicated time-points. The targeted tissues were harvested, sectioned, and stained for lacZ expression. (a and b) Front limb muscle from mice receiving in utero intra-muscular injection at days 21 and 91 after birth. (c and d) Liver tissue from mice receiving in utero intra-hepatic injection at days 14 and 70 after birth. Representative pictures are shown. Original magnification 40×.
kidney, heart, spleen, or intestine. 2, [13] [14] [15] [16] The expression pattern appeared to be stage-specific 2, 13 and, in some cases, lasted for over 2 months. 2 Mouse embryogenesis relevant to fetal gene therapy delivery strategies includes the development of the limb, the liver and regression of the decidua. The limb buds are well differentiated and have a clear proximal and distal margin by day 10 p.c. Paddle-shaped footplates become distinguishable on day 12 p.c. The hepatic diverticulum originates at the junction of the foregut and midgut at day 8-8.5 p.c. Hepatic parenchymal tissue is invaded by venous channels of vitelline vein origin to form hepatic sinusoids by day 10.5 p.c., with a gradual increase in parenchyma by day 12 p.c. to the point where the liver occupies a significant proportion of the abdominal cavity. 19 Thus, the limbs and liver are readily identifiable by day 12 for potential in utero injection strategies. The eye can be clearly identified at about the same time, concurrent with the development of the retro-orbital venus plexus. The intra-placental and intra-amniotic routes were chosen because they did not require direct injection into the fetus per se, and therefore might result in less damage to the fetus and improved survival.
The time of immune maturation varies among different strains of mice and ranges from day 18 p.c. to 2 weeks after birth. 20 With the above embryological and immunological considerations in mind, days 12-15 p.c. appears to be the ideal time-window for direct targeting of the fetal limb or liver. However, our preliminary experiments revealed that, compared with day 15 p.c. fetuses, intramuscular injection into day 13 p.c. fetuses required a smaller injection volume (2 l versus 5 l) and a much lower viral dose (Ͻ5 × 10 8 particles per fetus versus 2 × 10 10 particles per fetus) to limit mortality. Considering that virus-mediated transgene expression might be greatly diluted during fetal and neonatal development, it would be necessary to infect as many cells as possible in order to maintain expression at levels of therapeutic value. We therefore decided to focus our study on day 15 p.c. fetuses, in which a higher viral dose could be used.
Based on the previous work and our own experience, we decided to test five routes of viral delivery, ie injections into the amniotic cavity (intra-amniotic), the placenta (intra-placental), the liver (intra-hepatic), the retroorbital venus plexus (retro-orbital), and the front limb (intra-muscular). The intra-amniotic injection only resulted in lacZ expression in the skin and intestine. This was consistent with the fact that the fetus is soaked in the amniotic fluid and swallows the liquid. The intraplacental, intra-hepatic and retro-orbital injection of Ad.CMVlacZ all led to expression in the liver, suggesting that, as in adult animals, liver was the preferred target when the virus was given into the blood circulation. Each of these three routes has its advantages and disadvantages. Intra-placental injection was easy to perform and did not result in direct damage to the fetus. However, compared with the intra-hepatic and retro-orbital routes, a much higher viral dose was needed to reach the same level of lacZ expression in the liver. Moreover, it was the only injection route that led to significant lacZ expression in the dam's liver. This suggests leakage of virus into the maternal circulation, which might also explain why it was less efficient in delivering the virus to the fetal liver. The intra-hepatic injection was the most efficient route to deliver the virus exclusively to the liver. If the liver was accurately targeted, little lacZ expression was observed in other tissues except in abdominal muscles, which were probably infected by virus leaking out from the liver. However, targeting fetal liver was technically difficult. A misplaced needle often led to injection into the peritoneal cavity or other tissues, such as the abdominal wall, intestine or lung. Retro-orbital injection was not as liver-specific as intra-hepatic injection. Although LacZ expression was found predominantly in the liver, it was also detected at lower levels in the heart, lung and kidney. The intra-muscular (into the front limb muscle) route was muscle-specific and expression was usually restricted in the areas around the injection site. The liver lacZ expression detected at the high viral doses was probably due to the leakage of virus into the fetal circulation.
Taken together, it appears that the route of viral delivery determines the accessibility of fetal tissues to the incoming virus, thus defining the pattern of transgene expression. Other factors that may affect the pattern of transgene expression include the availability of adenoviral receptors and the vascularization of different fetal tissues at the time of viral injection. It was reported by Turkay et al 2 that expression of the integrin ␤3 subunit, which serves as part of the secondary adenoviral receptor complex, correlated with the stage-specific pattern of adenovirus-mediated gene expression. On the other hand, Schachtner et al 13 found that the expression pattern of murine coxsackievirus and adenovirus receptor (CAR), the primary receptor for adenovirus, was remarkably distinct from the pattern of transgene expression. Whether these receptors play a role during fetal infection remains to be determined.
We have demonstrated for the first time, to our knowledge, that an in utero injection of AAV resulted in prolonged lacZ expression in the liver and muscle. AAVmediated lacZ expression in the muscle persisted for at least 90 days with no signs of lymphocytic infiltration, which is in agreement with the vector's performance in adult animals. The expression efficiency in the liver was lower (Ͻ1% of total cells) but was relatively stable (up to 70 days). The low level of hepatic expression was probably due to the CMV promoter, which has been shown to be much less effective in the liver in the context of AAV vectors. 21 It is also possible that some of the viral genomes were lost during development. In contrast to adenovirus, AAV vectors showed very little toxicity in either intra-muscular or intra-hepatic routes. The survival rate was greater than 85% even at the highest dose tested. Better expression efficiency should be achievable with a more concentrated viral stock. However, the utility of this vector for in utero gene transfer needs to be further evaluated in animal models of genetic diseases.
Materials and methods
Mice Adult B6/129 F1 mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and were housed in the specific pathogen-free animal facility at the Children's National Medical Center. All animal experiments were carried out according to the institutional guidelines for animal use.
Preparation of adenoviral vectors
The E1-deleted recombinant adenovirus carrying the Escherichia coli lacZ gene encoding ␤-galactosidase (designated Ad.CBlacZ) was generated as previously described. 22 LacZ gene expression was controlled by the cytomegalovirus (CMV) enhancer and chicken ␤-actin Gene Therapy gene promoter. The virus was purified from a frozen cell lysate on the day of the injection, and was suspended in phosphate-buffered saline (PBS) at the desired concentrations.
Preparation of AAV vectors
Recombinant AAV vectors containing the ␤-galactosidase gene under the control of the CMV promoter (AAV.CMVlacZ) were produced as described by Xiao et al. 23 Briefly, the cis plasmid (with AAV ITRs), the trans plasmid (with the AAV rep and cap gene), and a helper plasmid (pF⌬6, which contains an essential region from the adenovirus genome) were cotransfected into 293 cells at a ratio of 1:1:2 by calcium phosphate precipitation. The cells were harvested 96 h later. The AAV was purified through two rounds of CsCl gradient purification, suspended in PBS and kept at 4°C.
In utero injection
To generate fetuses for in utero injection, 10-to 12-weekold female B6/129 F1 mice were mated with B6/129 F1 males for 1 night and checked for vaginal plugs the next morning. Mice bearing the plug were housed in individual cages and the day that the plug was found was counted as day 0 post-conception (p.c.). On the day of injection, the pregnant female mouse (day 15 p.c.) was anesthetized with Metofane (Pitman-Moore, Mundelein, IL, USA). A laparotomy was performed and the uterus was gently eviscerated with a pair of cotton-tipped applicators. Injection of fetuses was performed with a glass micropipette needle (diameter: 50-100 m, pulled with a P-30 needle puller and polished with a BV-10 beveler, both made by Sutter Instrument Co., Novato, CA, USA) through the uterine wall and into either the amniotic cavity, the placenta, the liver, the retro-orbital venus plexus, or the front limb of the fetus. Five microliters of virus were delivered for each injection. Control fetuses were injected with 5 l of PBS into the same locations. The uterus was returned to the abdominal cavity and the abdominal wall was then closed with sutures. The mouse was kept on a warm pad and returned to its cage after recovery.
Determination of ␤-galactosidase (␤-gal) activity in tissue samples
Frozen sections (10 m) of tissue were fixed in 0.5% glutaraldehyde at room temperature for 10 min, washed with PBS, and stained for 2 h at 37°C in PBS containing 5 mm K 3 Fe(CN) 6 , 5 mm K 4 Fe(CN) 6 , 1 mm MgCl 2 , and 1 mg/ml 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (Xgal). The sections were then counter-stained with hematoxylin and mounted for microscopic evaluation.
